The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders.

Abstract

Cognitive dysfunction is a principal determinant of functional impairment in major depressive disorder (MDD) and often persists during periods of euthymia. Abnormalities in the glutamate system, particularly in N-methyl-d-aspartate receptors (NMDARs) activity, have been shown to contribute to both mood and cognitive symptoms in MDD. The current narrative review aims to evaluate the potential pro-cognitive effects of targeting the glycine site of NMDARs in the treatment of psychiatric disorders, with a special focus on how these results may apply to MDD. Literature databases were searched from inception to May 2018 for relevant pre-clinical and clinical studies evaluating antidepressant and pro-cognitive effects of NMDAR glycine site modulators in both MDD and non-MDD samples. Six glycine site modulators with pro-cognitive and antidepressant properties were identified: d-serine (co-agonist), d-cycloserine (partial agonist), d-alanine (co-agonist), glycine (agonist), sarcosine (co-agonist) and rapastinel (partial agonist). Preclinical animal studies demonstrated improved neuroplasticity and pro-cognitive effects with these agents. Numerous proof-of-concept clinical trials demonstrated pro-cognitive and antidepressant effects trans-diagnostically (e.g., in healthy participants, MDD, schizophrenia, anxiety disorders, major neurocognitive disorders). The generalizability of these clinical studies was limited by the small sample sizes and the paucity of studies directly evaluating cognitive effects in MDD samples, as most clinical trials were in non-MDD samples. Taken together, preliminary results suggest that the glycine site of NMDARs is a promising target to ameliorate symptoms of depression and cognitive dysfunction. Additional rigorously designed clinical studies are required to determine the cognitive effects of these agents in MDD.

• Authors: Bahareh Peyrovian, Joshua D Rosenblat, Zihang Pan, Michelle Iacobucci, Elisa Brietzke, Roger S McIntyre
• Journal: Progress in neuro-psychopharmacology & biological psychiatry (Prog Neuropsychopharmacol Biol Psychiatry) Vol. 92 Pg. 387-404 (06 08 2019) ISSN: 1878-4216 [Electronic] England
• PMID: 30738126 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2019 Elsevier Inc. All rights reserved.

Chemical References

• Antidepressive Agents
• Nootropic Agents
• Receptors, N-Methyl-D-Aspartate

Topics

• Animals
• Antidepressive Agents (therapeutic use)
• Cognition Disorders (complications, drug therapy)
• Depressive Disorder, Major (complications, drug therapy)
• Humans
• Nootropic Agents (therapeutic use)
• Protein Binding (drug effects)
• Receptors, N-Methyl-D-Aspartate (agonists)